Inmune Bio, Inc 8-K, filed Dec 30, 2020
Inmune Bio, Inc. (INMB)
About this 8-K
Inmune Bio, Inc filed this 8-K on December 30, 2020, reporting on events of December 29, 2020.
Items reported
- Item 8.01: Other events
- Item 9.01: Financial statements and exhibits
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): December 29, 2020
| INMUNE BIO INC. | ||
| (Exact name of registrant as specified in charter) |
| Nevada | 001-38793 | 47-5205835 | ||
| (State or other jurisdiction | (Commission File Number) | (IRS Employer | ||
| of incorporation) | Identification No.) |
1200 Prospect Street, Suite 525, La Jolla, CA 92037
(Address of Principal Executive Offices) (Zip Code)
(858) 964 3720
(Registrant’s Telephone Number, Including Area Code)
Not Applicable
(Former Name or Former Address, If Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
| Common Stock, par value $0.001 per shares | INMB | The NASDAQ Stock Market LLC |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mart if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 8.01. Other Events.
INmune Bio Inc. (the “Company”) is filing as Exhibit 99.1 to this Current Report on Form 8-K is filing a Shareholder Letter dated December 29, 2020 that it sent to its shareholders. By filing this Current Report on Form 8-K and furnishing the information contained herein, the Company makes no admission as to the materiality of any information in this report that is required to be disclosed solely by reason of Regulation FD.
The information contained in the Investor Presentation is summary information that is intended to be considered in the context of the Company's Securities and Exchange Commission (“SEC”) filings and other public announcements that the Company may make, by press release or otherwise, from time to time. The Company undertakes no duty or obligation to publicly update or revise the information contained in this report, although it may do so from time to time as its management believes is warranted. Any such updating may be made through the filing of other reports or documents with the SEC, through press releases or through other public disclosure.
Item 9.01 Financial statements and Exhibits
(d) Exhibits.
| Exhibit Number | Description | |
| 99.1 | Shareholder Letter |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| INMUNE BIO INC. | ||
| Date: December 30, 2020 | By: | /s/ David Moss |
| David Moss | ||
| Chief Financial Officer | ||
Exhibit 99.1
December 29, 2020
Re: End-of Year Shareholder Letter 2020
In many ways, 2020 has been a strange year. Ten months ago, we were all living life “normally.” In March, the pandemic cast its deep shadow across every aspect of our daily lives. The virus has dictated our personal and professional lives. Like many, INMB has adapted and I dare say thrived. We had many accomplishments this year. The highlights include:
| · | INMB presented preliminary data from our Phase I trial using XPro1595 to tame neuroinflammation in patients with Alzheimer’s Disease (AD). These data, albeit preliminary, give us confidence that our strategy to target neuroinflammation as a cause of dementia is justified. With luck and hard work, we plan to start enrolling a Phase II trial during 2021. |
| · | Early in the COVID-19 pandemic, it became clear that the cytokine storm caused by COVID-19 was the cause of the symptoms that drive patients to seek medical attention. TNF is arguably the most important cytokine of the cytokine storm. Working closely with the FDA, we opened an IND for a Phase II trial to treat patients with respiratory compromise from COVID-19 infection. Although this is a blinded randomized trial that makes it impossible for us to see exactly what is happening, we believe Quellor is making a difference in both patients and the overburdened hospital system. |
| · | ![]() INMB
entered a second new therapeutic arena – treatment resistant depression (TRD). TRD is a big problem with few solutions. INMB
was awarded a $2.9M grant from the NIH to perform a biomarker directed Phase II study in patients with TRD. We believe we won the
award because of a novel trial design that integrates biomarkers into patient selection and outcome measures. INMB remains a leader
in the use of biomarkers in our CNS programs. As with the AD trial, we are using XPro1595 to target neuroinflammation. This will
be a recurring theme in our CNS programs. |
| · | Our programs in oncology with INKmune and INB03, and in NASH with LIVNate have been delayed by the burden of COVID-19 on the hospital systems and its impact on clinical trials. We do not expect things to return to “normal” until this time next year. |
| · | Last but not least, we have matured as a public company allowing completion of a meaningful $25M financing mid-year. These funds provide more than a year of runway given current programs and should allow us to reach important clinical and corporate milestones. |
2020 was eventful in ways that none of us anticipated at this time last year. INMB continues to make progress in these difficult times. We would not be here without shareholder support. We hope to make 2021 equally interesting. May all of you have a great holiday season. Stay safe, wear your mask, and please get vaccinated!
| RJ Tesi MD | David Moss | Mark Lowdell PhD |
| CEO and Founder | CFO and Founder | CSO and Founder |
|
![]() |
![]() |
www.inmunebio.com

INMB
entered a second new therapeutic arena – treatment resistant depression (TRD). TRD is a big problem with few solutions. INMB
was awarded a $2.9M grant from the NIH to perform a biomarker directed Phase II study in patients with TRD. We believe we won the
award because of a novel trial design that integrates biomarkers into patient selection and outcome measures. INMB remains a leader
in the use of biomarkers in our CNS programs. As with the AD trial, we are using XPro1595 to target neuroinflammation. This will
be a recurring theme in our CNS programs.

